Literature DB >> 3946775

Thiopentone levels during cardiopulmonary bypass. Changes in plasma protein binding during continuous infusion.

D J Morgan, D P Crankshaw, P R Prideaux, H N Chan, M D Boyd.   

Abstract

Plasma total and unbound concentrations of thiopentone were investigated during exponentially decreasing infusions in seven patients undergoing cardiopulmonary bypass. Total plasma thiopentone concentrations reached a plateau (10.2, SD 2.1 micrograms/ml) soon after the initial bolus dose and commencement of the infusion. Concentrations were maintained until the onset of cardiopulmonary bypass, whereupon total plasma thiopentone concentration fell abruptly to 50.0 (SD 5.8) percent of the prebypass level. The unbound fraction of thiopentone increased from 16.6 (SD 1.9) percent before bypass to a maximum of 29.3 (SD 5.6) percent during bypass (p less than 0.01), decreased to 22.9 (SD 3.3) percent at the end of bypass (p less than 0.01), but was still elevated 5-7 hours later (20.5, SD 2.5 percent). The result of the changes in binding was a smaller decline in unbound thiopentone concentration at the onset of bypass to 76.4 (SD 15.7) percent of the prebypass level. Also, unbound levels returned to the prebypass level by the end of bypass, whereas total levels remained low.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946775     DOI: 10.1111/j.1365-2044.1986.tb12695.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  5 in total

1.  Reduction by general anaesthetics of group Ia excitatory postsynaptic potentials and currents in the cat spinal cord.

Authors:  D M Kullmann; R L Martin; S J Redman
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

Review 2.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

3.  Propofol sequestration within the extracorporeal circuit.

Authors:  M Hynynen; E Hammarén; P H Rosenberg
Journal:  Can J Anaesth       Date:  1994-07       Impact factor: 5.063

4.  The effect of cardiopulmonary bypass on plasma protein binding of alfentanil.

Authors:  K Kumar; D P Crankshaw; D J Morgan; G H Beemer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.

Authors:  W A Buylaert; L L Herregods; E P Mortier; M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.